This week we received FDA authorization to measure ketamine’s psychedelic effect on the brain using Kernel Flow with our partner Cybin.

It is exciting to explore the possibilities of psychedelic therapeutics by enabling longitudinal brain activity measurement before, during and after a psychedelic experience, leading to quantifying what has been subjective patient reporting.

‍

‍